Keystone Symposia

This meeting took place in 2019

Here are the related meetings in 2020:
Antibodies as Drugs: From B Cell Biology to New Treatments (B1)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2)

Organizer(s) Christian Klein, Mark S. Cragg and Germaine Fuh
April 7—11, 2019
Beaver Run Resort • Breckenridge, CO USA
Discounted Abstract Deadline: Dec 11, 2018
Abstract Deadline: Jan 9, 2019
Scholarship Deadline: Dec 11, 2018
Discounted Registration Deadline: Feb 6, 2019

Sponsored by AbbVie Inc., Bioverativ Therapeutics, ImmunoGen, Inc., Incyte Corporation, Merck & Co., Inc., MorphoSys AG and Roche

Summary of Meeting:
Over the last 20 years, recombinant antibodies have been established into clinical practice for the treatment of diseases ranging from cancer, to autoimmune and infectious diseases. While the first approved antibodies were native IgG antibodies, in recent years the field has rapidly advanced and therapeutic antibodies in preclinical and clinical development now include many non-canonical formats including Fc- engineered antibodies, antibody drug conjugates, bispecific antibodies and antibody-like scaffolds. This Keystone Symposia conference aims to bring together experts in antibody therapeutics, engineering and mechanisms of action from industry and academia to discuss and review the state-of-the-art in the field and discuss their future potential. The conference will foster cross-fertilization between different engineering technologies and scientists from different therapeutic areas. This conference can also help to initiate collaboration on the development of state-of-the-art antibody therapies with the aim to improve therapeutic options for patients. For trainees and early career researchers, this conference provides an opportunity to gain insight into various aspects of therapeutic antibodies and to discuss their projects and ideas face-to-face with experts in the field. A unique component to this conference that distinguishes it from other more commercial meetings in the field, is that this conference will include presentation and discussion of novel/unpublished data.

View Meeting Program


National Institute of Allergy and Infectious Diseases (NIAID) Scholarship Recipients

Aliza Borenstein-Katz
Weizmann Institute, Israel

Chiara Figazzolo
University of Cambridge, UK

Brian H. Santich
Memorial Sloan Kettering Cancer Center, USA